Yahoo Finance2d
GenSight Biologics Announces Submission of LUMEVOQ® Dossier to ANSM to Prepare for Restart of Early Access Program in France
PARIS, November 13, 2024--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME ...
FierceBiotech21d
GenSight enters final weeks of cash runway as revenue stream edges out of reach
GenSight Biologics is weeks away from running out of money. Again. The biotech only has enough cash to fund operations into mid-November and, with a revenue stream set to start later than planned ...
Business Wire21d
GenSight Biologics Reports Cash Position as of September 30, 2024, and Provides Business Update
PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a ...
Yahoo Finance29d
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024
PARIS, October 17, 2024--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing ...
Business Wire13d
GenSight Biologics announces a financing for an amount of c. €2.8 million from existing investors
"We are truly grateful for the continuing support of Heights Capital and Sofinnova Partners,” noted Jan Eryk Umiastowski, Chief Financial Officer of GenSight Biologics. “The small bridge ...
Restoring sight is possible now with optogenetics
Other companies such as Paris-based biotechnology company GenSight Biologics and Bionic Sight in New York are also ...
Kepler Capital Reaffirms Their Hold Rating on GenSight Biologics SA (G49N)
In a report released on November 13, Justine Telliez from Kepler Capital maintained a Hold rating on GenSight Biologics SA (G49N – ...
Barron's3y
GenSight Biologics S.A.
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Morningstar29d
GenSight Biologics Announces LUMEVOQ® Scientific Updates at AAO 2024
GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative ...
Wall Street Journal6y
GenSight Biologics S.A.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
GenSight Biologics announces a financing for an amount of c. €2.8 million from existing investors
This press release is not being made in and copies of It may not be distributed or sent, directly or indirectly, into the United States, Canada, South Africa, Japan or Australia GenSight ...
Wall Street Journal3y
GenSight Biologics S.A.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...